Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TERT-induced adoptive T cell therapy - Eutilex

Drug Profile

TERT-induced adoptive T cell therapy - Eutilex

Alternative Names: hTERT; Telomerase reverse transcriptase-induced natural T cell therapy - Eutilex; TERT 4-1BB CTL - Eutilex; TERT-induced natural T cell therapy - Eutilex; TERTiNT - Eutilex

Latest Information Update: 28 Sep 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eutilex
  • Class Antineoplastics; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action CD8 positive T lymphocyte stimulants; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 28 Sep 2022 No recent reports of development identified for phase-I development in Solid-tumours in South Korea (Parenteral, Infusion)
  • 30 Sep 2020 TERT-induced adoptive T cell therapy is still in phase I trials for Solid tumour in South Korea (Eutilex pipeline, September 2020)
  • 06 Nov 2017 Phase-I clinical trials in Solid tumour in South Korea (Parenteral) before November 2017 (Eutilex pipeline, November 2017)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top